TechCrunch – A new drug for treating schizophrenia has just landed on the US market.
Paratek Pharmaceuticals has announced the release of a novel treatment for the disorder, which is believed to affect 1 in 100 Americans.
It’s the second new medication for schizophrenia to be approved by the Food and Drug Administration in less than two years, after its predecessor, Zytiga, was approved by regulators earlier this year.
It has been approved by US regulators, and will be available in the United States on Tuesday.
The company also revealed it has been working with other universities and health care providers in the US to develop a trial for a new form of Zytigazone that will be tested in the clinical trial.
This could help to increase the availability of Zetazone, the drug, in the market.
A company spokeswoman said: “The new Zetaza-based drug will be the first in a series of Zeta medications.”
This new drug is a first-in-class therapy for Zetazione and the Zetiazones used in the trial, Zetrazan-1 and Zetzane-1, has a shorter half-life, lower doses and is more effective than existing treatments.
“We are excited to be bringing the first-ever treatment for Zeta to the market in the U.S.
A second Zetza-based therapy is currently under development, but we are committed to developing new therapies to address the remaining side effects of ZETAZIN.”
A third Zetizane-based treatment is being developed in the same way, but is also not approved for the U: “We will work closely with the FDA to develop this treatment and to achieve its full approval,” said Paratek spokeswoman Ann Marie Stoecker.
Zetazin, the second-in a new class of Zytozadone drugs, is an antipsychotic drug that treats schizophrenia.
It works by inhibiting the activity of a protein known as P38 and by preventing the formation of new neurons.
In recent years, many researchers have been using Zyzadones to treat schizophrenia, but its efficacy and safety remain controversial.
The drug is approved for use in adults in the UK, Australia and New Zealand.